Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 387974 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
ElectronicAdd to Basket
Hard CopyAdd to Basket



The Pharmaceutical Market: Slovenia
Espicom Business Intelligence Ltd, Nov 2007, Pages: 72


  Description  
  Table of Contents  
  Summary  
    
    
   
 Enquire before Buying  
 Send to a Friend  

Slovenia is a small but relatively wealthy country, located in central Southern Europe. A part of Yugoslavia prior to 1991, Slovenia escaped from the collapse of that country virtually untouched by violence and ethnic warfare. In other respects, the country more closely resembles its Western neighbours rather than other former Communist states; demographic indicators are more in line with Western than Eastern Europe and income levels are comparable with those found in Southern parts of the European Union. The Slovenian pharmaceutical market is thus relatively advanced.
The country has a sizeable domestic industry and is home to the two largest generics companies in Europe, Krka and Lek. Slovenian pharmaceutical regulations are aligned with EU legislation, following EU entry in May 2004 and are enforced by the Agency for Medicinal Products and Medical Devices, of the MoH. Patent laws have come under fire in recent years, but the introduction of the 8+2+1 formula in April 2006 helped to prevent Slovenia being placed on the US 301 Watch List for 2007.

New pricing regulations came into effect in January 2007, which should save US$32 million of the US$690 million currently spent on prescription drugs at hospitals each year. Research companies have criticised the new legislation as the price of a patented drug is now matched to the lowest price in one of the reference countries, rather than the average. Generic prices must not exceed 85% of the average of a similar product.



Customers who bought this item also bought

Otsuka Pharmaceutical Co Deals Briefing

Teva Pharmaceutical Industries Ltd Deals Briefing

The Pharmaceutical Market: Ukraine

Takeda Pharmaceutical Co Ltd Deals Briefing

The Pharmaceutical Market: Australia

Indian Pharmaceutical Industry: Issues and Opportunities

Ono Pharmaceutical Co Deals Briefing

Daiichi Sankyo Co Ltd Deals Briefing



Top of page


   All rights reserved. Copyright 2008 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds